– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...

Antiviral improved overall patient-reported measures of both upper, lower respiratory symptoms, shortened overall course of illness COLLEGE PARK, Ga., May 7, 2025 /PRNewswire/ -- Altesa BioSciences ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 Dr. Brett Giroir, Chief Executive ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 AMSTERDAM, Sept. 28, 2025 ...